While both aim to serve the same growing need, their approaches differ significantly
As a triple-agonist compound simultaneously engaging GLP-1, GIP, and glucagon receptors, retatrutide requires sophisticated dosing strategies that account for its unique pharmacokinetic profile, receptor occupancy dynamics, and dose-dependent adverse event spectrum
They concluded that the main transporters of metformin are OCT1, PMAT, SERT and CHT, accounting for approximately 25%, 20%, 20% and 15% of apical metformin transport, respectively
It did not provide for protocols or specific GLP-1 strategies, or, for example, there are no rules that specifically limit the use of these GLP-1 type drugs only for diabetes
The typical timeline looks like this: Weeks 1 to 4 at a new dose Nausea and GI symptoms are most intense